Aurora A Is a Repressed Effector Target of the Chromatin Remodeling Protein INI1/hSNF5 Required for Rhabdoid Tumor Cell Survival

被引:76
作者
Lee, SeungJae [1 ]
Cimica, Velasco [1 ]
Ramachandra, Nandini [1 ]
Zagzag, David [2 ]
Kalpana, Ganjam V. [1 ]
机构
[1] Albert Einstein Coll Med, Dept Genet, New York, NY 10461 USA
[2] NYU, Dept Pathol & Neurosurg, New York, NY USA
关键词
KINASE INHIBITORS; INTEGRASE INTERACTOR-1; MITOTIC CHECKPOINT; ANTICANCER AGENTS; CYCLIN D1; CANCER; TRANSCRIPTION; EXPRESSION; HSNF5/INI1; MUTATIONS;
D O I
10.1158/0008-5472.CAN-10-2167
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Rhabdoid tumors (RT) are aggressive pediatric malignancies with poor prognosis. INI1/hSNF5 is a component of the chromatin remodeling SWI/SNF complex and a tumor suppressor deleted in RT. Previous microarray studies indicated that reintroduction of INI1/hSNF5 into RT cells leads to repression of a high degree of mitotic genes including Aurora Kinase A (Aurora A, STK6). Here, we found that INI1/SNF5 represses Aurora A transcription in a cell-type-specific manner. INI1-mediated repression was observed in RT and normal cells but not in non-RT cell lines. Chromatin immunoprecipitation (ChIP) assay indicated that INI1/hSNF5 associates with Aurora A promoter in RT and normal cells but not in non-RT cells. Real-time PCR and immunohistochemical analyses of primary human and mouse RTs harboring mutations in INI1/hSNF5 gene indicated that Aurora A was overexpressed/derepressed in these tumor cells, confirming that INI1/hSNF5 represses Aurora A in vivo. Knockdown of Aurora A impaired cell growth, induced mitotic arrest and aberrant nuclear division leading to decreased survival, and increased cell death and caspase 3/7-mediated apoptosis in RT cells (but not in normal cells). These results indicated that Aurora A is a direct downstream target of INI1/hSNF5-mediated repression in RT cells and that loss of INI1/hSNF5 leads to aberrant overexpression of Aurora A in these tumors, which is required for their survival. We propose that a high degree of Aurora A expression may play a role in aggressive behavior of RTs and that targeting expression or activity of this gene is a novel therapeutic strategy for these tumors. Cancer Res; 71(9); 3225-35. (C) 2011 AACR.
引用
收藏
页码:3225 / 3235
页数:11
相关论文
共 42 条
[1]   Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors [J].
Alarcon-Vargas, D ;
Zhang, Z ;
Agarwal, B ;
Challagulla, K ;
Mani, S ;
Kalpana, GV .
ONCOGENE, 2006, 25 (05) :722-734
[2]   The integrase interactor I (INII) proteins facilitate Tat-mediated human immunodeficiency virus type I transcription [J].
Ariumi, Yasuo ;
Serhan, Fatima ;
Turelli, Priscilla ;
Telenti, Amalio ;
Trono, Didier .
RETROVIROLOGY, 2006, 3 (1)
[3]   Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB [J].
Betz, BL ;
Strobeck, MW ;
Reisman, DN ;
Knudsen, ES ;
Weissman, BE .
ONCOGENE, 2002, 21 (34) :5193-5203
[4]  
Biegel Jaclyn A, 2006, Neurosurg Focus, V20, pE11
[5]  
Carpinelli P, 2009, CURR OPIN DRUG DISC, V12, P533
[6]   Amplification and overexpression of Aurora kinase A (AURKA) in immortalized human ovarian epithelial (HOSE) cells [J].
Chung, CM ;
Man, C ;
Jin, Y ;
Jin, C ;
Guan, XY ;
Wang, Q ;
Wan, TSK ;
Cheung, ALM ;
Tsao, SW .
MOLECULAR CARCINOGENESIS, 2005, 43 (03) :165-174
[7]   The chromatin-remodeling BAF complex mediates cellular antiviral activities by promoter priming [J].
Cui, KR ;
Tailor, P ;
Liu, H ;
Chen, X ;
Ozato, K ;
Zhao, K .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (10) :4476-4486
[8]   Members of the hSWI/SNF chromatin remodeling complex associate with. and are phosphorylated by protein kinase B/Akt [J].
Foster, K. S. J. ;
McCrary, W. J. ;
Ross, J. S. ;
Wright, C. F. .
ONCOGENE, 2006, 25 (33) :4605-4612
[9]   Roles of aurora kinases in mitosis and tumorigenesis [J].
Fu, Jingyan ;
Bian, Minglei ;
Jiang, Qing ;
Zhang, Chuanmao .
MOLECULAR CANCER RESEARCH, 2007, 5 (01) :1-10
[10]   Aurora kinases as anticancer drug targets [J].
Gautschi, Oliver ;
Heighway, Jim ;
Mack, Philip C. ;
Purnell, Phillip R. ;
Lara, Primo N., Jr. ;
Gandara, David R. .
CLINICAL CANCER RESEARCH, 2008, 14 (06) :1639-1648